Javascript must be enabled to continue!
IABP Versus Impella Support in Cardiogenic Shock: “In Silico” Study
View through CrossRef
Cardiogenic shock (CS) is part of a clinical syndrome consisting of acute left ventricular failure causing severe hypotension leading to inadequate organ and tissue perfusion. The most com-monly used devices to support patients affected by CS are Intra-Aortic Balloon Pump (IABP), Impella 2.5 pump and Extracorporeal Membrane Oxygenation. The aim of this study is the com-parison between Impella and IABP using CARDIOSIM© software simulator of the cardiovascular system. The results of the simulations included baseline conditions from a virtual patient in CS followed by IABP assistance in synchronized mode with different driving and vacuum pressures. Subsequently, the same baseline conditions were supported by the Impella 2.5 with different ro-tational speeds. The percentage variation with respect to baseline conditions was calculated for hemodynamic and energetic variables during IABP and Impella assistance. Impella pump driven with a rotational speed of 50000 rpm increased the total flow by 4.36% with a reduction in left ventricular end diastolic volume (LVEDV) by ≅15% to ≅30%. A reduction in left ventricular end systolic volume (LVESV) by ≅10% to ≅18% (≅12% to ≅33%) was observed with IABP (Impella) as-sistance. Taking into account the limitations of a simulation setting, this study highlights that assistance with the Impella device leads to higher reduction in LVESV, LVEDV, left ventricular external work and left atrial pressure-volume loop area compared to IABP support.
Title: IABP Versus Impella Support in Cardiogenic Shock: “In Silico” Study
Description:
Cardiogenic shock (CS) is part of a clinical syndrome consisting of acute left ventricular failure causing severe hypotension leading to inadequate organ and tissue perfusion.
The most com-monly used devices to support patients affected by CS are Intra-Aortic Balloon Pump (IABP), Impella 2.
5 pump and Extracorporeal Membrane Oxygenation.
The aim of this study is the com-parison between Impella and IABP using CARDIOSIM© software simulator of the cardiovascular system.
The results of the simulations included baseline conditions from a virtual patient in CS followed by IABP assistance in synchronized mode with different driving and vacuum pressures.
Subsequently, the same baseline conditions were supported by the Impella 2.
5 with different ro-tational speeds.
The percentage variation with respect to baseline conditions was calculated for hemodynamic and energetic variables during IABP and Impella assistance.
Impella pump driven with a rotational speed of 50000 rpm increased the total flow by 4.
36% with a reduction in left ventricular end diastolic volume (LVEDV) by ≅15% to ≅30%.
A reduction in left ventricular end systolic volume (LVESV) by ≅10% to ≅18% (≅12% to ≅33%) was observed with IABP (Impella) as-sistance.
Taking into account the limitations of a simulation setting, this study highlights that assistance with the Impella device leads to higher reduction in LVESV, LVEDV, left ventricular external work and left atrial pressure-volume loop area compared to IABP support.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
What is the evidence for IABP in STEMI with and without cardiogenic shock?
What is the evidence for IABP in STEMI with and without cardiogenic shock?
Intraaortic balloon pump (IABP) is the most widely used left ventricular support device in a variety of indications. This review focuses on the current literature and discusses the...
Hemodynamic analysis of left ventricular unloading with Impella versus IABP during VA-ECMO
Hemodynamic analysis of left ventricular unloading with Impella versus IABP during VA-ECMO
Purpose
The utilization of intra-aortic balloon pump (IABP) and Impella has been suggested as means of left ventricular unloading in veno-arterial extracorporeal membrane oxyg...
Abstract 4366123: Impella Use in AMI-Related Cardiogenic Shock is Associated with Increased Mortality and Complications Compared to Intra-Aortic Balloon Pump: A Propensity-Matched Real-World Analysis
Abstract 4366123: Impella Use in AMI-Related Cardiogenic Shock is Associated with Increased Mortality and Complications Compared to Intra-Aortic Balloon Pump: A Propensity-Matched Real-World Analysis
Background:
Mechanical circulatory support is often employed in acute myocardial infarction (AMI) complicated by cardiogenic shock. While Impella and IABP are w...
Infection on the Sidelines: Evaluating Bacteremia Rates in Device-Dependent Cardiology Patients
Infection on the Sidelines: Evaluating Bacteremia Rates in Device-Dependent Cardiology Patients
Introduction:
Patients with mechanical circulatory support (MCS) devices, such as ventricular assist devices (VAD) and extracorporeal membrane oxygenation (ECMO...
IABP Versus Impella Support in Cardiogenic Shock: “In Silico” Study
IABP Versus Impella Support in Cardiogenic Shock: “In Silico” Study
Cardiogenic shock (CS) is part of a clinical syndrome consisting of acute left ventricular failure causing severe hypotension leading to inadequate organ and tissue perfusion. The ...

